11C-radiolabeled aptamer for imaging of tumors and metastases using positron emission tomography- computed tomography

• Main Authors: Anastasia V. Ozerskaya (Author), Tatiana N. Zamay (Author), Olga S. Kolovskaya (Author), Nikolay A. Tokarev (Author), Kirill V. Belugin (Author), Natalia G. Chanchikova (Author), Oleg N. Badmaev (Author), Galina S. Zamay (Author), Irina A. Shchugoreva (Author), Roman V. Moryachkov (Author), Vladimir N. Zabluda (Author), Vladimir A. Khorzhevskii (Author), Nikolay Shepelevich (Author), Stanislav V. Gappoev (Author), Elena A. Karlova (Author), Anastasia S. Saveleva (Author), Alexander A. Volzhentsev (Author), Anna N. Blagodatova (Author), Kirill A. Lukyanenko (Author), Dmitry V. Veprintsev (Author), Tatyana E. Smolyarova (Author), Felix N. Tomilin (Author), Sergey S. Zamay (Author), Vladimir N. Silnikov (Author), Maxim V. Berezovski (Author), Anna S. Kichkailo (Author)
• Format: Book
• Published: Elsevier, 2021-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Summary

Identification of primary tumors and metastasis sites is an essential step in cancer diagnostics and the following treatment. Positron emission tomography-computed tomography (PET/CT) is one of the most reliable methods for scanning the whole organism for malignancies. In this work, we synthesized an 11C-labeled oligonucleotide primer and hybridized it to an anti-cancer DNA aptamer. The 11C-aptamer was applied for in vivo imaging of Ehrlich ascites carcinoma and its metastases in mice using PET/CT. The imaging experiments with the 11C-aptamer determined very small primary and secondary tumors of 3 mm2 and less. We also compared 11C imaging with the standard radiotracer, 2-deoxy-2-[fluorine-18]fluoro-D-glucose (18F-FDG), and found better selectivity of the 11C-aptamer to metastatic lesions in the metabolically active organs than 18F-FDG. 11C radionuclide with an ultra-short (20.38 min) half-life is considered safest for PET/CT imaging and does not cause false-positive results in heart imaging. Its combination with aptamers gives us high-specificity and high-contrast imaging of cancer cells and can be applied for PET/CT-guided drug delivery in cancer therapies.

Item Description

2162-2531
10.1016/j.omtn.2021.10.020